WebDoctor Encyclopedia

Acute leukaemias

Acute promyelocytic leukaemia (APL)

Acute promyelocytic leukaemia (APL) is a fast-growing subtype of acute myeloid leukaemia caused by the PML-RARA gene fusion. It often starts with serious bleeding but is now highly curable.

Medically reviewed Last reviewed October 21, 2026

What is acute promyelocytic leukaemia?

Acute promyelocytic leukaemia (APL) is a fast-growing blood cancer. It is a distinct subtype of acute myeloid leukaemia (AML) in which immature white blood cells called promyelocytes build up in the bone marrow and blood.

APL is caused by one specific gene change, a fusion of the PML and RARA genes. This fusion blocks the cells from maturing. It also makes the leukaemia cells release substances that upset blood clotting, so APL often starts with serious bleeding.

APL is a medical emergency. Without fast treatment, many people die in the first days or weeks, mainly from bleeding in the brain or lungs.

The good news is that APL is now one of the most curable leukaemias. Two medicines that target the PML-RARA protein, all-trans retinoic acid (ATRA) and arsenic trioxide (ATO), cure around 9 in 10 people who get through the first weeks of treatment.

1. Key facts at a glance

Feature Details
Share of AML About 5-15% of adult AML cases
Typical age Mostly young and middle-aged adults; median age about 40-45. Less common in children and older people
Sex Men and women are affected about equally
Populations Reported more often in people of Latin American (Hispanic) origin
Cause An acquired fusion of the PML gene (chromosome 15) and the RARA gene (chromosome 17), usually from the translocation t(15;17)
Main danger A clotting disorder that causes bleeding and, less often, clots
Main treatment ATRA plus arsenic trioxide, with chemotherapy added for high-risk disease
Outlook Long-term survival about 90% or more in people who complete treatment

2. Causes and risk factors

2.1 The PML-RARA fusion

In almost all cases of APL, parts of chromosome 15 and chromosome 17 swap places. This is called the translocation t(15;17)(q24;q21). It joins the PML gene to the RARA gene (retinoic acid receptor alpha).

Normally, RARA responds to vitamin A (retinoic acid) and helps white blood cells mature. The fused PML-RARA protein jams this process. The cells get stuck at the promyelocyte stage and keep dividing.

ATRA and arsenic trioxide both work by breaking down the PML-RARA protein. This lets the leukaemia cells mature and die. APL is one of the clearest examples in medicine of a cancer cured by drugs that hit its root cause.

2.2 Rare variant forms

In about 1-2% of cases, RARA is joined to a different partner gene. The 2022 WHO classification lists these separately as AML with other RARA rearrangements. This matters for treatment:

Partner gene Response to ATRA Response to arsenic
NPM1-RARA, NUMA1-RARA Usually sensitive Variable
ZBTB16 (PLZF)-RARA Resistant Resistant
STAT5B-RARA Resistant Resistant

People with resistant variants are treated with standard AML chemotherapy.

2.3 Risk factors

There is usually no clear cause, and APL is not inherited. Known or suspected risk factors include:

Risk factor Notes
Previous cancer treatment Therapy-related APL can follow chemotherapy with topoisomerase II drugs (for example mitoxantrone or epirubicin) or radiotherapy, often for breast cancer or multiple sclerosis
Ethnic background Higher rates in people of Latin American origin
Obesity Linked to APL in some studies

3. How does it look?

APL is diagnosed in the laboratory, but some features can be seen on the body and many are visible under the microscope.

3.1 Signs on the body

Sign What it looks like
Petechiae Tiny red or purple pin-point spots on the skin, often on the legs or inside the mouth
Bruises (ecchymoses) Large bruises after minor knocks, or with no injury at all
Bleeding gums and nosebleeds Oozing that is hard to stop
Bleeding from needle sites Blood seeping from drip or blood-test sites
Pale skin Caused by anaemia
Eye changes Bleeding in the white of the eye or the retina

Unlike some other leukaemias, APL rarely causes large lymph nodes, a big spleen or swollen gums from leukaemia cells.

3.2 Under the microscope

Feature Description
Abnormal promyelocytes Large cells packed with coarse pink-purple granules that may hide the nucleus
Nucleus Often folded or two-lobed, sometimes called “butterfly” or “bilobed”
Auer rods Needle-shaped crystals in the cytoplasm. They can be seen in other AMLs too, but in APL they are often numerous
Faggot cells Cells that contain bundles of many Auer rods, like a bundle of sticks; very typical of APL
Microgranular (hypogranular) variant About 15-20% of cases. Granules are too fine to see, nuclei are strongly two-lobed, and the white count is usually high

3.3 Laboratory pattern

Test Typical result in APL
Full blood count Low platelets and anaemia. White count is usually low in classic APL but high in the microgranular variant
Clotting tests Low fibrinogen, high D-dimer and a prolonged prothrombin time: the picture of disseminated intravascular coagulation (DIC) with strong fibrinolysis
Flow cytometry Cells positive for CD33 and CD13 (often CD117), and usually negative for HLA-DR and CD34; the microgranular variant may express CD2 and CD34
Cytochemistry Strongly positive for myeloperoxidase
Genetic tests t(15;17) on karyotype; PML-RARA fusion by FISH and RT-PCR

4. Symptoms

Symptoms of APL usually develop over days to a few weeks. They come from two problems: the leukaemia crowding out normal blood cells, and the clotting disorder.

4.1 Symptoms from low blood counts

Symptom Cause
Tiredness, weakness, breathlessness Anaemia (low red cells)
Pale skin, dizziness, fast heartbeat Anaemia
Fever and infections Too few working white cells (neutrophils)
Easy bruising and red spots Low platelets

4.2 Symptoms from the clotting disorder

Bleeding is the most important symptom of APL. It is often worse than the platelet count alone would suggest.

Type of bleeding or clotting Examples
Skin and mucous membranes Bruises, petechiae, bleeding gums, nosebleeds
Heavy periods Very heavy or prolonged menstrual bleeding
Blood in urine, stools or vomit Bleeding in the kidneys, bladder or gut
Bleeding in the brain Sudden severe headache, confusion, weakness, fits or drowsiness; this is the leading cause of early death
Bleeding in the lungs Coughing blood, breathlessness
Blood clots Less common; deep vein thrombosis, lung clots or stroke

4.3 When to get urgent help

Go to an emergency department straight away if you have:

  • bleeding that will not stop, or many new bruises or red spots
  • a sudden severe headache, confusion, vision changes, weakness or trouble speaking
  • coughing or vomiting blood
  • a high fever with low blood counts

If APL is suspected, doctors start ATRA immediately, even before genetic tests confirm the diagnosis.

5. Diagnosis

Step Purpose
Blood count and blood film Shows low counts and abnormal promyelocytes
Clotting screen Fibrinogen, D-dimer, prothrombin time and aPTT; repeated at least daily early on
Bone marrow sample Confirms the leukaemia and gives cells for genetic tests. Often done from a blood sample alone if bleeding risk is high
PML-RARA by FISH or RT-PCR Confirms the diagnosis, often within hours to a day; RT-PCR also identifies the transcript type for later monitoring
Karyotype Detects t(15;17) and other chromosome changes
Kidney and liver tests, electrolytes Baseline before treatment
ECG and heart scan Checks the QT interval before arsenic, and heart function before anthracyclines
Pregnancy test ATRA and arsenic can harm an unborn baby

5.1 Risk groups

Doctors divide APL into risk groups using the white blood cell count (WBC) at diagnosis, based on the Sanz score:

Risk group White cell count Usual approach
Low or intermediate (non-high) risk 10 x 109/L or less ATRA plus arsenic trioxide, without chemotherapy
High risk Above 10 x 109/L ATRA plus arsenic with an anthracycline (such as idarubicin) or gemtuzumab ozogamicin, or ATRA plus chemotherapy

6. Treatment

6.1 Emergency care in the first days

The first priority is to stop bleeding and start ATRA at once. The European LeukemiaNet (ELN) recommends:

Measure Target or note
Start ATRA on suspicion Do not wait for genetic confirmation
Platelet transfusions Keep platelets above 30-50 x 109/L
Fibrinogen replacement Cryoprecipitate or fibrinogen concentrate to keep fibrinogen above 1-1.5 g/L
Fresh frozen plasma To correct a prolonged clotting time
Avoid invasive procedures Central lines, lumbar punctures and other procedures are delayed if possible
Heparin and tranexamic acid Not routinely recommended

6.2 Standard-risk APL: ATRA plus arsenic

For non-high-risk APL, ATRA plus arsenic trioxide without chemotherapy is the standard of care. In the Italian-German APL0406 trial, it was better than ATRA plus chemotherapy:

Result (about 4 years) ATRA + arsenic ATRA + chemotherapy
Event-free survival 97% 80%
Overall survival 99% 93%

Treatment has two phases:

Phase What happens Length
Induction Daily ATRA tablets and arsenic infusions until complete remission Usually 4-8 weeks, often in hospital
Consolidation Courses of ATRA and arsenic to remove the remaining leukaemia About 7 months in total

Maintenance treatment is not needed after ATRA plus arsenic. In China, an oral arsenic preparation (realgar-indigo naturalis formula) was as effective as intravenous arsenic in a randomised trial, and allows much of treatment to be given at home.

6.3 High-risk APL

People with a high white cell count have more early bleeding and more relapses. Options include:

Approach Evidence
ATRA + arsenic + idarubicin or gemtuzumab ozogamicin Used in the UK AML17 and Australasian APML4 trials. The APOLLO trial (2025) found ATRA plus arsenic with a short course of idarubicin better than ATRA plus chemotherapy
ATRA + anthracycline chemotherapy (AIDA-type) The older standard, often followed by 2 years of maintenance
Hydroxyurea To control a rising white count during ATRA plus arsenic

6.4 Main side effects and complications

Problem What it is How it is managed
Differentiation syndrome Affects about 1 in 4 people. Maturing leukaemia cells release chemicals that cause fever, breathlessness, fluid on the lungs, weight gain, low blood pressure and kidney problems Dexamethasone 10 mg twice daily at the first sign; ATRA or arsenic may be paused. Steroids are often given as prevention when the white count is high
QT prolongation (arsenic) A change in heart rhythm that can rarely cause dangerous arrhythmias Regular ECGs; keep potassium and magnesium normal; avoid other QT-prolonging drugs; pause if QTc is above 500 ms
High white count Common on ATRA plus arsenic Hydroxyurea
Liver changes Raised liver enzymes Dose pause or reduction
ATRA effects Headache, dry skin and lips, raised blood fats, and raised pressure in the skull (pseudotumour cerebri), especially in children Painkillers, moisturisers, dose reduction
Infections More frequent with chemotherapy Antibiotics and antifungals as needed

6.5 Monitoring for remaining disease

Doctors check for PML-RARA with sensitive RT-PCR tests. The key goal is a negative test at the end of consolidation (molecular remission).

Group Usual monitoring after treatment
Standard risk, PCR negative after consolidation Further routine testing may be limited, as relapse is rare
High risk PCR every 3 months for about 2-3 years
PCR becomes positive again Repeat test within 2-4 weeks; confirmed molecular relapse is treated straight away

6.6 Relapsed APL

Relapse is uncommon after modern treatment (about 5% in standard risk). It is usually treated with arsenic-based therapy, often with ATRA. A second molecular remission is often followed by:

Situation Usual next step
PCR negative in second remission Autologous stem cell transplant (using your own stem cells)
PCR still positive Allogeneic stem cell transplant (from a donor)
Brain or spinal fluid involvement Treatment into the spinal fluid; sometimes radiotherapy

7. Special situations

Situation Key points
Children Treated with similar ATRA and arsenic regimens, with lower ATRA doses to reduce headache and pseudotumour cerebri. Outcomes are excellent
Older adults ATRA plus arsenic is usually well tolerated and avoids chemotherapy
Pregnancy Arsenic is avoided throughout pregnancy. ATRA is avoided in the first trimester; in the second and third trimesters ATRA, often with an anthracycline, can be used. A specialist team plans care
Therapy-related APL Responds to the same treatment as other APL, with similar results

8. Outlook (prognosis)

Measure Approximate figure
Complete remission 90-100% in clinical trials
Early death in trials About 5% or less
Early death in everyday practice Higher, about 10-20% in population studies, mostly from bleeding before or soon after diagnosis
Long-term survival (standard risk, ATRA + arsenic) Over 90%
Long-term survival (high risk) About 80-90%

The biggest danger is in the first two weeks. Prompt recognition and starting ATRA early save lives. Once remission is reached, most people are cured and can return to normal life.

9. Living with and after APL

Topic Practical advice
During induction Expect a hospital stay of several weeks with daily blood tests
Bleeding precautions Use a soft toothbrush and electric razor; avoid aspirin and ibuprofen unless your team agrees
Infection precautions Report a temperature of 38 C or more straight away
Contraception Use reliable contraception during treatment and for the time your team advises afterwards
Vaccines Inactivated vaccines are usually fine; avoid live vaccines during treatment unless your team says otherwise
Late effects After anthracyclines, long-term heart checks may be advised; after ATRA plus arsenic alone, late effects are few

10. Frequently asked questions

Question Answer
Is APL the same as AML? APL is a subtype of AML, but it is treated very differently and has a much better outlook
Is arsenic a poison? In high doses, yes. In carefully measured medical doses it is a highly effective targeted cancer drug
Is APL inherited? No. The gene fusion is acquired in the blood cells and is not passed to children
Will I need a stem cell transplant? Not usually. Transplants are mainly used after a relapse
Should I avoid vitamin A? ATRA is a form of vitamin A. Avoid vitamin A supplements during treatment unless your doctor advises otherwise
Can I have children afterwards? Many people do. ATRA plus arsenic is thought to have little effect on fertility, but discuss fertility before treatment if possible

Resources

  1. Khoury, J.D. et al. (2022) ‘The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: Myeloid and Histiocytic/Dendritic Neoplasms’, Leukemia, 36(7), pp. 1703-1719.
  2. Arber, D.A. et al. (2022) ‘International Consensus Classification of Myeloid Neoplasms and Acute Leukemias: integrating morphologic, clinical, and genomic data’, Blood, 140(11), pp. 1200-1228.
  3. Sanz, M.A. et al. (2019) ‘Management of acute promyelocytic leukemia: updated recommendations from an expert panel of the European LeukemiaNet’, Blood, 133(15), pp. 1630-1643.
  4. de The, H., Pandolfi, P.P. and Chen, Z. (2017) ‘Acute promyelocytic leukemia: a paradigm for oncoprotein-targeted cure’, Cancer Cell, 32(5), pp. 552-560.
  5. Lo-Coco, F. et al. (2013) ‘Retinoic acid and arsenic trioxide for acute promyelocytic leukemia’, New England Journal of Medicine, 369(2), pp. 111-121.
  6. Platzbecker, U. et al. (2017) ‘Improved outcomes with retinoic acid and arsenic trioxide compared with retinoic acid and chemotherapy in non-high-risk acute promyelocytic leukemia: final results of the randomized Italian-German APL0406 trial’, Journal of Clinical Oncology, 35(6), pp. 605-612.
  7. Burnett, A.K. et al. (2015) ‘Arsenic trioxide and all-trans retinoic acid treatment for acute promyelocytic leukaemia in all risk groups (AML17): results of a randomised, controlled, phase 3 trial’, The Lancet Oncology, 16(13), pp. 1295-1305.
  8. Iland, H.J. et al. (2015) ‘Use of arsenic trioxide in remission induction and consolidation therapy for acute promyelocytic leukaemia in the Australasian Leukaemia and Lymphoma Group (ALLG) APML4 study: a non-randomised phase 2 trial’, The Lancet Haematology, 2(9), pp. e357-e366.
  9. Platzbecker, U. et al. (2025) ‘Arsenic trioxide and all-trans retinoic acid combination therapy for the treatment of high-risk acute promyelocytic leukemia: results from the APOLLO trial’, Journal of Clinical Oncology, 43(29), pp. 3160-3169.
  10. Zhu, H.H. et al. (2018) ‘Oral arsenic plus retinoic acid versus intravenous arsenic plus retinoic acid for non-high-risk acute promyelocytic leukaemia: a non-inferiority, randomised phase 3 trial’, The Lancet Oncology, 19(7), pp. 871-879.
  11. Sanz, M.A. et al. (2000) ‘Definition of relapse risk and role of nonanthracycline drugs for consolidation in patients with acute promyelocytic leukemia: a joint study of the PETHEMA and GIMEMA cooperative groups’, Blood, 96(4), pp. 1247-1253.
  12. Park, J.H. et al. (2011) ‘Early death rate in acute promyelocytic leukemia remains high despite all-trans retinoic acid’, Blood, 118(5), pp. 1248-1254.
  13. Montesinos, P. et al. (2009) ‘Differentiation syndrome in patients with acute promyelocytic leukemia treated with all-trans retinoic acid and anthracycline chemotherapy: characteristics, outcome, and prognostic factors’, Blood, 113(4), pp. 775-783.
  14. Lo-Coco, F., Hasan, S.K., Montesinos, P. and Sanz, M.A. (2013) ‘Biology and management of therapy-related acute promyelocytic leukemia’, Current Opinion in Oncology, 25(6), pp. 695-700.
  15. National Cancer Institute (2026) Acute Myeloid Leukemia Treatment (PDQ) – Health Professional Version. Available at: https://www.cancer.gov/types/leukemia/hp/adult-aml-treatment-pdq (Accessed: October 2026).

Prepared by the editorial team, October 2026.